Место иммуноонкологии в лечении немелкоклеточного рака легкого
Автор: Лактионов Константин Константинович, Саранцева Ксения Андреевна, Бредер Валерий Владимирович, Окружнова Мария Александровна, Перегудова Марина Валерьевна
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Фундаментальная онкология и экспериментальная медицина
Статья в выпуске: 3 (19), 2016 года.
Бесплатный доступ
Немелкоклеточный рак легкого (НМРЛ) является ведущей причиной смертности от онкологических заболеваний во всем мире. При применении стандартной химиотерапии не удалось достигнуть хороших результатов долгосрочной выживаемости у пациентов с метастатическим НМРЛ. При наличии драйверных мутаций назначение таргетной терапии позволяет добиться хорошего ответа и значительного увеличения показателя выживаемости без прогрессирования. Однако только около у 25%-30% пациентов с НМРЛ выявляются эти мутации. Таким образом, для лечения рака легкого актуальна разработка новых подходов терапии. Недавно было показано, что иммуноонкология является эффективным подходом во второй линии терапии НМРЛ. Этот прогресс был достигнут благодаря разработке препаратов ингибиторов рецептора PD-1 и лиганда PD-L1. В этом обзоре мы рассмотрим данные исследований, доступные для этих препаратов в настоящее время.
Нмрл, иммуноонкология, ингибиторы контрольных точек
Короткий адрес: https://sciup.org/140222654
IDR: 140222654 | DOI: 10.18027/2224-5057-2016-3-18-26
Список литературы Место иммуноонкологии в лечении немелкоклеточного рака легкого
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29.
- Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015; 136(5): 359-86.
- Kaprin A.D., Starinskij V.V., Petrova G.V. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2014 g. M.-2015.
- Davydov M.I., Polockij B.E. «Sovremennye principy vybora lechebnoj taktiki i vozmozhnosti hirurgicheskogo lecheniya nemelkokletochnogo raka legkogo», sbornik Novoe vterapii raka legkogo. M-2003.
- Cheng D. et ai. Video-Assisted Thoracic Surgery in Lung Cancer Resection: A Meta-Analysis and Systematic Review of Controlled Trials. Innovations (Philadelphia). 2007; 2(6): 261-292.
- Detterbeck F.C., Postmus P.E., Tanoue L.T. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5): 191-210.
- Tanoue L.T., Detterbeck F.C. New TNM classification for nonsmall-cell lung cancer. Expert review of anticancer therapy. 2009; 9(4): 413-423.
- Pishchik V.G. et al. Pervyj opyt vypolneniya torakoskopicheskih lobehktomij s bronhoplastikoj. Vestnik hirurgii imeni 1.1. Grekova. 2015; 174(1): 59-65
- Downey R.G. et al. Video-Assisted Thoracic Surgery for Lung Cancer Resection: A Consensus Statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2007. Innovations (Philadelphia). 2007; 2(6); 293-302.
- Tyulyandin S.A., Polockij B.E. Taktika lecheniya nemelkokletochnogo raka legkogo MIC-IV stadii. Prakticheskaya onkologiya. 2006; 7 (3): 161-169.
- Orlova R.V. Sovremennoe standartnoe lechenie bol’nyh nemelkokletochnym rakom legkogo s uchetom stadii zabolevaniya. Prakticheskaya onkologiya. 2000; 3:17-20.
- Ramnath N. et al. Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013; 143 (5): 314-340.
- Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IMA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13(8): 1880-92.
- Le Chevalier T., Arriagada R., Quoix E. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
- Marenich A.F., Gorbunova V.A., Rodnikova E.G., Fedenko A.A. Kolesnik A.A. «Raznoobrazie rezhimov kombinirovanoj himioterapii v lechenii nemelkokletochnogo raka legkogo». Trudnyj pacient, M.-2007.
- Bansal P., Osman D., Gan G.N., Simon G.R., Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol. 2016; 6:112.
- Asciertoa P.A., Marincolab F.M. 2015: The year of anti-PD-1/PD-L1s against melanoma and beyond. EBioMedicine. 2015; 2 (2): 92-93.
- Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, со-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12): 1365-1369.
- Bickels J., Kollender Y., Merinsky O., Meller I. Coley’s toxin: historical perspective. The Israel Medical Association journal: IMAJ. 2002; 4: 471-2.
- Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23 (8): 6-9.
- Ascierto P. A. et al. What have we learned from cancer immunotherapy in the last 3 years? Journal of Translational Medicine. 2014,12:141.
- Hiraoka K., Miyamoto M., Cho Y. et al. Concurrent infiltration by CD8+ T cells and CD4+ Tcells is a favourable prognostic factor in non-small cell lung carcinoma. Br J Cancer. 2006; 94(2): 275-80.
- Al-Shibli K.I., Donnern T., Al-saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clin. Cancer Res. 2008; 14:5220-5227.
- Kawai O., Ishii G., Kubota K. et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant www.malignanttumours.org • № 3-2016 r. (19) • MALIGNANT TUMOURS 25 ФУНДАМЕНТАЛЬНАЯ ОНКОЛОГИЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНА • FUNDAMENTAL ONCOLOGY AND EXPERIMENTAL MEDICINE predictor of survival in stage IV non-small cell lung cancer. Cancer. 2008;113:1387-1395.
- Petersen R.P., Campa M.J., Sperlazza J. et al. Tumor infiltrating Foxp3+ regulatory T cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107: 2866-2872.
- Shimizu K., Nakata M., Hirami Y. et al. Tumor infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resrcted non-small cell lung cancer. J. Thorac. Oncol. 2010; 5:585-590.
- Mayor M., Yang N., Sterman D., Jones D.R., Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg. 2016; 49(5):1324-33.
- Pennell N.A. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Semin Oncol. 2015; 42 (2): 3-10.
- Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11 (11): 3887-95.
- Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med. 2002; 8:793-800.
- Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004; 4(5): 336-347.
- Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19:813-2.
- Riley J.L. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114-25.
- Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer response. Clin Cancer Res. 2013; 19:5542.
- Ota K., Azuma K., Kawahara A., et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.Clin Cancer Res. 2015; 21:4014-21.
- Pan Z.K., Ye F., Wu X., et al. Clinicopathological and prognostic significance of programmed cell death ligandl (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.J Thorac Dis. 2015; 7:462-70.
- Gettinger S.N., Horn L., Gandhi L., et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death
- Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18): 2004-12.
- Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21): 2018-28.
- Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123-35.
- Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627-39.
- Herbst R.S., Baas P., Kim D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-ОЮ): a randomised controlled trial. Lancet. 2016; 387(10027): 1540-50.
- Fehrenbacher L., Spira A., Ballinger M. et al. Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomized controlled trial. Lancet. 2016; 387(10030): 1837-46.
- Chae Y.K., Pan A., Davis A.A., et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a GoodMarker for Patient Selection? Clin Lung Cancer. 2016: S1525-7304 (16): 30057-2.
Статья научная
